(112), (137)
Disease-modifying antirheumatic drugs along with biological agents act by immune system suppression and may be associated with increased susceptibility to infections and cancers.
Ustekinumab and secukinumab are considered biological
disease-modifying antirheumatic drugs (bDMARDs), like the TNF inhibitors, while apremilast occupies a new classification niche as a targeted synthetic DMARD, said Dr.
There was significant interaction between
disease-modifying antirheumatic drug (DMARD) use and disease group (P < .001 for MACE and two components, CV death and cerebrovascular accident; and P = .01 for MI).
This study, which will be run by Vertex, will evaluate once-daily (QD) and twice-daily (BID) doses of VX-509 in combination with methotrexate, a commonly prescribed
disease-modifying antirheumatic drug (DMARD) for RA that is frequently used in combination with other RA medicines.
Patients in the TEAR trial had active disease with a mean disease duration of 3.6 months and a mean disease activity 28 (DAS28) score of 5.8, had not received prior
disease-modifying antirheumatic drug (DMARD) therapy, and had a poor prognosis based on the findings of rheumatoid factor positivity, a positive cyclic citrullinated peptide antibody test, or the presence of at least two erosions.
In addition to the combination
disease-modifying antirheumatic drug (DMARD) regimen, patients received placebo or infliximab in doses of 3 mg/kg at weeks 4, 6, 10, 18, and 26, and were followed for 2 years.
None had prior
disease-modifying antirheumatic drug (DMARD) treatment.
No other significant associations were seen, including current use of tumor necrosis factor blockers,
disease-modifying antirheumatic drug, or corticosteroids.
SNOWMASS, COLO.--Screening for both hepatitis C and B is a reasonable strategy in all patients who are under consideration for any
disease-modifying antirheumatic drug. "If they turn out to be infected, you've done them a huge favor.
The trial is a non-inferiority design and it randomised 1,262 patients with moderately to severely active RA who have not had an adequate response to
disease-modifying antirheumatic drug (DMARD) therapies which may have included (in up to 20% of patients) one or more tumour necrosis factor (TNF) antagonist therapies into two treatment arms.
The enrolled JIA patients failed prior treatment with at least one
disease-modifying antirheumatic drug. Patients were an average age of 12 years old (range, 6-17 years), and they had been diagnosed with JIA for an average of 4 years.